Emerging clinical role of ranolazine in the management of angina

References

• BruntonTLOn the use of nitrite of amyl in angina pectorisLancet1867909798
   Google Scholar
• RosamondWFlegalKFurieKHeart disease and stroke statistics 2008 update: A report from the American Heart AssociationStatistics Committee and Stroke Statistics CommitteeCirculation2008117e25e146
   Google Scholar
• BodenWEO’RourkeRATeoKKOptimal medical therapy with or without PCI for stable coronary diseaseN Engl J Med20073561503151617387127
   PubMed Web of Science ®Google Scholar
• FryeRLAugustPBrooksMMBARI 2D Study GroupA randomized trial of therapies for Type 2 diabetes and coronary artery diseaseN Engl J Med20093602503251519502645
   PubMed Web of Science ®Google Scholar
• FreemantleNClelandJYoungPMasonJHarrisonJβ blockade after myocardial infraction: Systematic review and meta regression analysisBr Med J19993181730173710381708
   PubMed Web of Science ®Google Scholar
• KernisSJHarjaiKJStoneGWDoes beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplastyJ Am Coll Cardiol2004431773177915145098
   PubMed Web of Science ®Google Scholar
• FrakerTDFihnSD2007chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable anginaJ Am Coll Cardiol2007502264227418061078
   PubMed Web of Science ®Google Scholar
• VadnaisDSWengerNKManagement options in chronic stable angina pectoris: Focus on ranolazineClin Med Ther20091871877
   Google Scholar
• BersDMBarryWHDespaSIntracellular Na+ regulation in cardiac myocytesCardiovasc Res20035789791212650868
   PubMed Web of Science ®Google Scholar
• MurphyECrossHSteenbergenCSodium regulation during ischemia versus reperfusion and its role in injuryCirc Res1999841469147010381900
   PubMed Web of Science ®Google Scholar
• BelardinelliLAntzelevitchCFraserHInhibition of late (sustained/persistent) sodium current: A potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte functionEur Heart J20046Suppl I1317
   Web of Science ®Google Scholar
• ChaitmanBRSkettinoSLParkerJOMARISA InvestigatorsAnti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe anginaJ Am Coll Cardiol2004431375138215093870
   PubMed Web of Science ®Google Scholar
• MacInnesAFairmanDABindingPThe antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolaseCirc Res200393e26e3212869391
   PubMed Web of Science ®Google Scholar
• SabbahHNChandlerMPMishimaTRanolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failureJ Card Fail2002841642212528095
   PubMed Web of Science ®Google Scholar
• McCormackJGBarrRLWolffAALopaschukGDRanolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat heartsCirculation1996931351428616920
   PubMed Web of Science ®Google Scholar
• LétienneRViéBPuechAVieuSLe GrandBJohnGWEvidence that ranolazine behaves as a weak β1- and β2-adrenoceptor antagonist in the rat cardiovascular systemNaunyn Schmiedebergs Arch Pharmacol200136346447111330341
   PubMed Web of Science ®Google Scholar
• WangPFraserHLloydSGMcVeighJJBelardinelliLChathamJCA comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusionJ Pharmacol Exp Ther200732121322017202401
   PubMed Web of Science ®Google Scholar
• HaleSLShryockJCBelardinelliLSweeneyMKlonerRALate sodium current inhibition as a new cardioprotective approachJ Mol Cell Cardiol20084495496718462746
   PubMed Web of Science ®Google Scholar
• BelardinelliLShryockJCFraserHInhibition of the late sodium current as a potential cardioprotective principle: Effects of the late sodium current inhibitor ranolazineHeart200692Suppl IV614
   Google Scholar
• ChaitmanBRRanolazine for the treatment of chronic angina and potential use in other cardiovascular conditionsCirculation20061132462247216717165
   PubMed Web of Science ®Google Scholar
• AntzelevitchCBelardinelliLZygmuntACElectrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic propertiesCirculation200411090491015302796
   PubMed Web of Science ®Google Scholar
• SicouriSGlassABelardinelliLAntzelevitchCAntiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparationsHeart Rhythm200851019102618598958
   PubMed Web of Science ®Google Scholar
• SongYShryockJCBelardinelliLAn increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytesAm J Physiol Heart Circ Physiol2008294H203120918310511
   PubMed Web of Science ®Google Scholar
• UndrovinasABelardinelliLUndrovinasNASabbahHNRanolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium currentJ Cardiovasc Electrophysiol200617Suppl 1S16917716686675
   PubMedGoogle Scholar
• SongYShryockJCWuLBelardinelliLAntagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytesJ Cardiovasc Pharmacol20044419219915243300
   PubMed Web of Science ®Google Scholar
• RousseauMFPouleurHCoccoGWolffAAComparative efficacy of ranolazine versus atenolol for chronic angina pectorisAm J Cardiol20059531133615670536
   PubMed Web of Science ®Google Scholar
• ChaitmanBRPepineCJParkerJEffects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with chronic severe angina: A randomized controlled trialJAMA200429130931614734593
   PubMed Web of Science ®Google Scholar
• StonePGratsianskyNABlokhinAHuangIZMengLAntianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trialJ Am Coll Cardiol20064856657516875985
   PubMed Web of Science ®Google Scholar
• FDA.govRanexa (Ranolazine); updated June 19, 2009 http://www.fda.gov/Accessed May 21, 2010
   Google Scholar
• VenkataramanRBelardinelliLBlackburnBHeoJIskandrianAEA study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion imagesJACC Cardiovasc Imaging200921301130919909934
   PubMed Web of Science ®Google Scholar
• MorrowDASciricaBMKarwatowska-ProkopczukEEffects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromesJAMA20072971775178317456819
   PubMed Web of Science ®Google Scholar
• SciricaBMMorrowDABudajAIschemia detected on continuous electrocardiography after acute coronary syndrome: Observations from the MERLIN-TIMI 36 (metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome – thrombolysis in myocardial infarction 36) trialJ Am Coll Cardiol2009531411142119371824
   PubMed Web of Science ®Google Scholar
• WengerNKChaitmanBVetrovecGWGender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trialsAm J Cardiol200799111817196454
   PubMed Web of Science ®Google Scholar
• WilsonSRSciricaBMBraunwaldEEfficacy of ranolazine in patients with chronic angina: Observations from the randomized, double- blind, placebo-controlled MERLIN-TIMI (metabolic efficiency with ranolazine for less ischemia in non-ST-segment elevation acute coronary syndromes) 36 trialJ Am Coll Cardiol2009531510151619389561
   PubMed Web of Science ®Google Scholar
• KorenMJCragerMRSweeneyMLong-term safety of a novel antianginal agent in patients with severe chronic stable angina: The ranolazine open label experience (ROLE)J Am Coll Cardiol2007491027103417349881
   PubMed Web of Science ®Google Scholar
• RichMWCragerMMcKayCRSafety and efficacy of extended-release ranolazine in patients aged 70 years or older with chronic stable angina pectorisAm J Geriatr Cardiol20071621622117617747
   PubMedGoogle Scholar
• TimmisADChaitmanBRCragerMEffects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetesEur Heart J200627424816176940
   PubMed Web of Science ®Google Scholar
• JerlingMClinical pharmacokinetics of ranolazineClin Pharmacokinet20064546949116640453
   PubMed Web of Science ®Google Scholar
• JerlingMAbdallahHEffect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazineClin Pharmacol Ther20057828829716153399
   PubMed Web of Science ®Google Scholar
• AbdallahHJerlingMEffect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tabletsJ Clin Pharmacol20054580280915951470
   PubMed Web of Science ®Google Scholar
• JerlingMHuanBLLeungKChuNAbdallahHHusseinZStudies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem or simvastatin during combined administration in healthy subjectsJ Clin Pharmacol20054542243315778423
   PubMed Web of Science ®Google Scholar
• BurashnikovADi DiegoJMZygmuntACBelardinelliLAntzelevitchCAtrial-selective sodium channel block as a strategy for suppression of atrial fibrillationAnn N Y Acad Sci2008112310511218375582
   PubMed Web of Science ®Google Scholar
• MurdockDKOvertonNKerstenMKaliebeJDevecchiFThe effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillationIndian Pacing Electrophysiol J2008817518118679523
   PubMedGoogle Scholar
• MurkockDKKerstenMKaliebeJLarrainGThe use of oral ranolazine to convert new or paroxysmal atrial fibrillation: A review of experience with implications for possible “pill in the pocket” approach to atrial fibrillationIndian Pacing Electrophysiol J2009926026719763194
   PubMedGoogle Scholar
• SossallaSKallmeyerBWagnerSAltered Na+ currents in atrial fibrillation: Effects of ranolazine on arrhythmias and contractility in human atrial myocardiumJ Am Coll Cardiol2010552330234220488304
   PubMed Web of Science ®Google Scholar
• KumarKNearingBDBartoliCRKwakuKFBelardinelliLVerrierRLEffect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heartJ Cardiovasc Electrophysiol2008191073107918479333
   PubMed Web of Science ®Google Scholar
• DhallaAKWangWQDowJRanolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusionAm J Physiol Heart Circ Physiol2009297H1192311929
   Web of Science ®Google Scholar
• WangWQRobertsonCDhallaAKBelardinelliLAntitorsadogenic effects of (±)-N-(2,6-Dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy) propyl]-1-piperazine (ranolazine) in anesthetized rabbitsJ Pharmacol Exp Ther200832587588118322148
   PubMed Web of Science ®Google Scholar
• MossAJZarebaWSchwarzKQRoseroSMcNittSRobinsonJLRanolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long QT syndromeJ Cardiovasc Electrophysiol2008191289129318662191
   PubMed Web of Science ®Google Scholar
• SciricaBMMorrowDAHodHEffect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment elevation acute coronary syndrome: Results from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trialCirculation20071161647165217804441
   PubMed Web of Science ®Google Scholar
• HayashidaWvan EyllCRousseauMFPouleurHEffects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart diseaseCardiovasc Drugs Ther199487417477873471
   PubMed Web of Science ®Google Scholar
• HwangHArcidiJMJrHaleSLRanolazine as a cardioplegia additive improves recovery of diastolic function in isolated rate heartsCirculation2009120Suppl 1S162119752362
   PubMedGoogle Scholar
• WuYSongYBelardinelliLShryockJCThe late Na+ current (INa) inhibitor ranolazine attenuates effects of palmitoyl-L-carnitine to increase late INa and cause ventricular diastolic dysfunctionJ Pharmacol Exp Ther200933055055719403851
   PubMed Web of Science ®Google Scholar
• SossallaSWagnerSRasenackECLRanolazine improves diastolic dysfunction in isolated myocardium from failing human hearts – role of late sodium current and intracellular ion accumulationJ Mol Cell Cardiol200845324318439620
   PubMed Web of Science ®Google Scholar
• HaleSLLeekaJLKlonerRAImproved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channelJ Pharmacol Exp Ther200631841842316617168
   PubMed Web of Science ®Google Scholar
• RastogiSSharovVGMishraSRanolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failureAm J Physiol Heart Circ Physiol2008295H2149215518820026
   PubMed Web of Science ®Google Scholar
• ChandlerMPStanleyWCMoritaHShort-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failureCirc Res20029127828012193459
   PubMed Web of Science ®Google Scholar
• StonePRanolazine: New paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmiasCardiol Clin20082660361418929234
   PubMed Web of Science ®Google Scholar
• GrundySMBenjaminIJBurkeGLDiabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart AssociationCirculation19991001134114610477542
   PubMed Web of Science ®Google Scholar
• MorrowDASciricaBMChaitmanBREvaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trialCirculation20091192032203919349325
   PubMed Web of Science ®Google Scholar